.png){kind=icon}
.png){kind=icon}
Return
Drug-induced liver injury secondary to tirzepatide
.png){kind=icon}
PRE
AI
C
M
H
DOI：10.1136/bcr-2025-269172.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Tirzepatide is a dual gastric inhibitory polypeptide and glucagon-like peptide-1 receptor agonist, used for the treatment of type 2 diabetes mellitus and obesity. While gastrointestinal side effects are well described in the literature, hepatotoxicity is not a recognised complication. Recent case reports have emerged describing drug-induced liver injury associated with tirzepatide. We present a case of a woman aged in her 20s who developed acute hepatocellular injury within four weeks of commencing tirzepatide. Extensive investigations did not reveal an alternative cause of liver injury. Following the cessation of tirzepatide, the patient demonstrated clinical and biochemical recovery over the following four weeks.
Keywords:
Gastrointestinal system
Drugs: endocrine system
Drugs: gastrointestinal system
Liver disease
General practice / family medicine
Journal
IF:
0.5
Papers:
929
Citations:
1.2W
Organization
Cited Papers